Diabetes Archives - San Diego Biotechnology Connection

More insurers, ObamaCare to cover obesity drugs made by Arena, Vivus

Circadian clock drugs coming to treat cancer, diabetes, other diseases

Buyout looming, Amylin ‘fast tracks’ treatment for rare lipodystrophy

Medistem signs stem-cell license for diabetes treatment with Yale

Europe approves BYETTA to treat type 2 diabetes

Stock Daily Change

Biotech Events in San Diego

@SDBiotech

San Diego Biotechnology Connection

Qsymia capsules, Vivus, Inc., San Diego Biotechnology Connection

November 27, 2012 no comments

By Rex Graham This season of pumpkin pie, mashed potatoes and rising obesity rates is a perfect time to talk turkey about the overly bearish sales estimates of Belviq and Qsymia, the obesity drugs ap Read More

Human circadian clock, San Diego Biotechnology Connection

August 13, 2012 no comments

By Rex Graham Potential circadian clock drugs with relevance to a broad spectrum of diseases from cancer and diabetes to sleep disorders are the offshoots of discoveries reported this year that expla Read More

Amylin requests 'fast track" on new drug to treat Lipodystrophy

April 8, 2012 no comments

By Rex Graham Amid news reports that Bristol-Myers Squibb (BMY) wants to buy Amylin Pharmaceuticals (AMLN) after Amylin balked at the larger company’s $22-per-share cash offer, Amylin announced that Read More

Mouse islet cells, Solimena Lab, San Diego Biotechnology Connection

March 27, 2012 no comments

San Diego-based Medistem Inc. and Yale University have signed an exclusive worldwide stem-cell license agreement covering the generation of pancreatic islets from stem cells such as the Endometrial R Read More

Byetta, Amylin Pharmaceuticals, San Diego Biotechnology Connection

March 23, 2012 no comments

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced in a March 23 news release that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an ad Read More

ADMP	0.668	+0.06
AEMD	0.105	-0.0038
AHRO	0.73	0.00
AIMM	0.0035	0.00
AMGN	104.24	+2.06
ANX	0.733	0.00
APRI	3.41	+0.06
ARNA	7.99	+0.03
ATEC	1.95	+0.03
AVNR	3.27	-0.07
AVTO	0.005	0.00
AXMP	0.012	0.00
AXRX	0.16	0.00
CADX	6.99	+0.12
CELG	123.50	+0.38
CORX	0.04	-0.01
CXM	0.091	+0.001
CYTX	2.54	+0.04
CYTR	2.42	0.00
DRAD	2.44	+0.04
DXCM	21.13	-0.11
ENTB	0.002	-0.0004
FOLD	3.46	+0.05
HALO	7.59	+0.02
HRBR	0.1887	-0.0003
IAGXQ	0.14	+0.03
ILMN	72.58	-0.50
IMBI	0.028	0.00
ISCO	0.30	+0.023
ISIS	20.81	+0.35
IVRO	0.017	-0.0028
LGND	27.74	+0.17
LIFE	73.68	+0.11
LJPC	0.075	-0.0004
LPTN	4.90	-0.05
MCK	118.41	+0.39
MEDS	1.20	0.00
MEIP	8.48	-0.06
MLPH	0.018	-0.002
MNKD	5.36	+0.05
MNOV	3.18	-0.24
MRIC	1.18	0.00
NAII	4.68	-0.07
NBIX	12.06	+0.05
NRDCQ	0.0001	0.00
NUXP	0.0016	0.00
ONCS	0.3205	-0.0035
OPTR	14.43	-0.27
OREX	6.11	+0.09
PCRX	28.84	+0.40
PFE	28.78	+0.08
QDEL	22.65	-0.20
RHHBY	64.71	+1.18
RMD	50.08	+0.10
SNTS	22.30	+0.20
SQNM	4.06	-0.05
TSRX	7.77	-0.11
VOLC	16.74	+0.08
VRX	75.53	+0.15
VRNM	2.15	-0.09
VVUS	13.16	+0.18
ZGNX	1.52	-0.05

2013-05-21 15:57

Trius Therapeutics: New, Positive Dimension For Investment Outlook http://t.co/rcVXC57kkN $CBST $TEVA $TSRX
8 days ago
Retweet
@ilus_art Gorgeous way to celebrate art, biology and cells.
16 days ago
Retweet
Trius Therapeutics releases persuasive safety study of potent new antibiotic against MRSA #superbug. http://t.co/uRBiPHj14U
22 days ago
Retweet
Halozyme initiates Phase 2 trial of drug to treat stage 4 pancreatic cancer. http://t.co/U9cjxGbtIL
28 days ago
Retweet
Illumina’s stronger than expected revenue up 21% sends shares up 13%. http://t.co/qviU0MYLQ3
28 days ago
Retweet
Trius presenting clinical-trial results Apr. 27 http://t.co/MCFeBYi57w on tedizolid, a potent MRSA antibiotic. http://t.co/myB421ZD2n
28 days ago
Retweet
After Thermo Fisher Scientific buys Life Technologies, sequencing leader Illumina may finally sell. http://t.co/F92ndBP0z2
36 days ago
Retweet
http://t.co/y8xbsAQ4q8
60 days ago
Retweet
FDA reviewing diabetes drugs causing pancreas precancers. Affected: Lilly, Merck, Novo Nordisk, Bristol-Myers. http://t.co/2dPyRAYLsc
67 days ago
Retweet

21 Events on May 21, 2013 Rising Above the Storm by Investing in Science and Technology Starts: 11:00 am Ends: May 21, 2013 - 12:00 pm Location: Scripps Research Inst. - Molecular Biology Building 2N, Committee Lecture Hall Description: Frontiers In Microbial Pathogenesis Symposium Speaker: Rino Rappuoli, Ph.D., Global Head of Vaccine Research, Novartis Vaccines & Diagnostics, Siena, Italy Read More: <a href="http://onlinelibrary.wiley.com/doi/10.1111/nyas.12046/abstract?deniedAccessCustomisedMessage=&userIsAuthenticated=false">link</a> More details...

23 Events on May 23, 2013 Studies Toward the Synthesis of Antitumor Natural Products Starts: 4:00 pm Ends: May 23, 2013 - 5:00 pm Location: Scripps Research Inst. - Green Hospital Building, Valerie Timken Amphitheater Description: Distinguished Lecture Series Speaker: John A. Porco, Ph.D., Professor, Department of Chemistry, Boston University Read More: <a href="http://pubs.rsc.org/en/content/articlelanding/2013/np/c3np20122h">link</a> More details...

The share price of Trius Therapeutics (TSRX) has rebounded almost fully from its 10 percent dip in the New Year that was triggered by its public offering of 7 million shares; however, uncertainty about the company’s lead investigational drug is a lingering February hangover. Small investors face a dilemma: should they dump their diluted shares, double down? Our story explains why we recommend doubling down: http://sandiegobiotechnology.com/topics/5733/trius-dump-or-double-down-on-maker-of-mrsa-antibiotic/
99 days ago
A Glaxo Smith Kline genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc., and San Diego-based Vical, Inc., offer new hope. http://sandiegobiotechnology.com/topics/5600/glaxo-genital-herpes-vaccine-flops-but-genocea-a-buy-in-vaccine-space/
158 days ago
The Dow was off 1.82 percent, down 243.36 points to 13,102.53 at the close of trading Oct. 23 amid disappointing earnings reports. But 11 publicly traded San Diego biotechs gained for the day. https://sandiegobiotechnology.com/topics/5443/eleven-san-diego-biotech-stocks-rise-amid-tuesday-plunge-in-dow/
210 days ago
Millions of infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis (PGD), which identifies their healthiest embryos at in vitro fertilization (IVF) clinics. These blastocysts, embryos with 50-150 cells, are at a very favorable stage for implantation and pregnancy. The inner cell mass will give rise to the actual cells of the fetus. The other cells that surround and protect the inner cell mass give rise to the fetal part of the placenta. Photo: Robert Shabanowitz, Gesinger Medical Center
211 days ago
It’s more than a 5-hour energy jolt. Cardium Therapeutics’ purchase of To Go Brands and its nationwide marketing network will give the San Diego biotech company a permanent sales boost for its own nutritional supplements -- and a larger piece of the $30 billion supplements market. https://sandiegobiotechnology.com/topics/5393/cardium-boosts-energy-supplement-sales-with-national-marketing-muscle/
231 days ago